AMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B

Research output: Contribution to journalArticlepeer-review


  • M. Johanns
  • M. F. Hsu
  • R. Jacobs
  • D. Vertommen
  • J. Van Sande
  • J. E. Dumont
  • A. Woods
  • D. Carling
  • L. Hue
  • B. Viollet
  • M. Foretz
  • M. H. Rider

Colleges, School and Institutes

External organisations

  • Duve Institute
  • University of Taipei
  • Université Libre de Bruxelles
  • Hammersmith Hospital
  • Institut Cochin
  • Paris Descartes University


Biguanides such as metformin have previously been shown to antagonize hepatic glucagon-stimulated cyclic AMP (cAMP) signalling independently of AMP-activated protein kinase (AMPK) via direct inhibition of adenylate cyclase by AMP. Here we show that incubation of hepatocytes with the small-molecule AMPK activator 991 decreases glucagon-stimulated cAMP accumulation, cAMP-dependent protein kinase (PKA) activity and downstream PKA target phosphorylation. Moreover, incubation of hepatocytes with 991 increases the Vmax of cyclic nucleotide phosphodiesterase 4B (PDE4B) without affecting intracellular adenine nucleotide concentrations. The effects of 991 to decrease glucagon-stimulated cAMP concentrations and activate PDE4B are lost in hepatocytes deleted for both catalytic subunits of AMPK. PDE4B is phosphorylated by AMPK at three sites, and by site-directed mutagenesis, Ser304 phosphorylation is important for activation. In conclusion, we provide a new mechanism by which AMPK antagonizes hepatic glucagon signalling via phosphorylation-induced PDE4B activation.


Original languageEnglish
Article number10856
JournalNature Communications
Publication statusPublished - 8 Mar 2016


  • Cell Signalling, Kinases, Medical research, Phosphorylation